Buy Repatha (evolocumab)

What is Repatha (evolocumab) for?

Buy Repatha (evolocumab). Repatha (evolocumab) is a PCSK9 inhibitor antibody. It helps lower fats in the blood. It’s used to treat:

• adults with cardiovascular disease to reduce heart attack, stroke, and heart surgery risks.
• adults with high cholesterol, called primary hyperlipidemia (including HeFH), to lower LDL or bad cholesterol. It’s used with diet alone or with other cholesterol medicines.
• people with homozygous familial hypercholesterolemia (HoFH) to lower LDL cholesterol. It’s used with other LDL-lowering medicines.

It’s not known if it’s safe and effective in children with HoFH under 13 or in children without HoFH.

It comes as a solution for injection in pre-filled syringes (140 mg), pens (140 mg), and cartridges (420 mg). The cartridges are used with an automated dosing device called a mini-doser.

How does Repatha (evolocumab) work?

Evolocumab, the active substance in Repatha, is a monoclonal antibody. It blocks PCSK9. PCSK9 can bind to cholesterol receptors on liver cells.

This lets these receptors be broken down and recycled. Repatha increases these receptors on the cell surface. This allows them to remove LDL cholesterol from the blood.

In patients with mixed dyslipidaemia, Repatha can also lower other fatty substances in the blood.

Where has Repatha (evolocumab) been approved?

Repatha (evolocumab) was approved by:

• The Food and Drug Administration (FDA), USA:
  • on August 27, 2015 to treat adults with HeFH, HoFH, or cardiovascular disease.
  • on December 1, 2017 to prevent heart attack and stroke.
• The European Medicines Agency (EMA):
  • on July 17, 2015 to treat adults with HeFH, HoFH, or cardiovascular disease.
• Health Canada:
  • on September 15, 2015 to treat adults with HeFH, HoFH, or cardiovascular disease.
  • on June 19, 2018 to prevent heart attack and stroke.
• Pharmaceuticals and Medical Devices Agency (PMDA), Japan:
  • on January 21, 2016 to treat adults with HeFH, HoFH, or cardiovascular disease.

This medicine may also be approved in other regions. If you have a question about its approval in a specific country, feel free to contact our support team.

How is Repatha (evolocumab) taken?

The standard dosage is:

• For adults with primary hypercholesterolaemia, mixed dyslipidaemia and atherosclerotic heart disease:
• 140 mg every two weeks, or
• 420 mg (3 pre-filled syringes or 1 cartridge) once a month.
• For adults and children aged 12 years and older with HoFH:

• 420 mg once a month.
• After 12 weeks, your treating doctor may decide to increase the dose to 420 mg every two weeks.

Inject the medicine of a prefilled pen or syringe under the skin (subcutaneous) into the thigh, upper arm, or stomach (abdomen).

It is used in combination with standard of care treatment.

Complete information about Repatha (evolocumab) dosage (modifications) and administration can be found in the official prescribing information listed in our references section.

Note: Please consult with your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Repatha (evolocumab)?

Common adverse reactions

The most common side effects ( ≥5% of patients) listed in the prescribing information include:

• Runny nose
• Sore throat
• Symptoms of the common cold, flu or flu-like symptoms
• Back pain
• High blood sugar levels (diabetes)
• Redness, pain, or bruising at the injection site.

Serious adverse reactions

The serious adverse reactions listed in the prescribing information include:

• Serious allergic reactions

Use in a specific population

It is not known whether Repatha (evolocumab) can harm a fetus. Tell your doctor if you get pregnant during treatment.

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information.

Buy Orladeyo (berotralstat)